Top

Pediatric Nephrology

Published in:

01-11-2018 | Original Article

Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients

Authors: Mark R. Hanudel, Marciana Laster, Georgina Ramos, Barbara Gales, Isidro B. Salusky

Published in: Pediatric Nephrology | Issue 11/2018

Abstract

Background

Ferric citrate, an iron-based phosphate binder, has been shown to improve both hyperphosphatemia and iron deficiency in adult chronic kidney disease patients, but its use in the pediatric dialysis population has not been described.

Methods

This is a retrospective analysis of 11 unselected pediatric dialysis patients who received ferric citrate as a phosphate binder between 2015 and 2017. Time-averaged laboratory values were compared pre- and post-ferric citrate initiation using the Wilcoxon signed-rank test.

Results

The median age of this cohort was 13 years old (range 4–17 years old). Five patients were on hemodialysis, and six patients were on peritoneal dialysis. The median duration of ferric citrate therapy was 214 days (range 39–654 days), with a median time-averaged ferric citrate dose of 3.5 tablets per day (range 1.5–8.4 tablets per day). Compared to the pre-ferric citrate period, ferric citrate treatment was associated with decreased serum phosphate (6.5 to 5.2 mg/dl, p = 0.014), decreased phosphate age-related standard deviation score (SDS) (2.3 to 0.9, p = 0.019), increased transferrin saturation (26 to 34%, p = 0.049), increased ferritin (107 to 230 ng/ml, p = 0.074), and maintenance of hematocrit.

Conclusions

In pediatric dialysis patients, ferric citrate may be able to concurrently lower phosphate levels and treat iron deficiency. However, larger studies are needed to further evaluate safety and efficacy in the pediatric chronic kidney disease population.

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl:S1–S130. https://doi.org/10.1038/ki.2009.188 CrossRef

Hsu CY, McCulloch CE, Curhan GC (2002) Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 13:504–510CrossRefPubMed

Yamada S, Giachelli CM (2017) Vascular calcification in CKD-MBD: roles for phosphate, FGF23, and Klotho. Bone 100:87–93CrossRefPubMed

Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL (2005) Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 16:520–528CrossRefPubMed

Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208–2218CrossRefPubMed

Fishbane S, Pollack S, Feldman HI, Joffe MM (2009) Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol 4:57–61CrossRefPubMedPubMedCentral

Klip IT, Jankowska EA, Enjuanes C, Voors AA, Banasiak W, Bruguera J, Rozentryt P, Polonski L, van Veldhuisen DJ, Ponikowski P, Comin-Colet J, van der Meer P (2014) The additive burden of iron deficiency in the cardiorenal-anaemia axis: scope of a problem and its consequences. Eur Journal Heart Fail 16:655–662CrossRef

Shah HH, Hazzan AD, Fishbane S (2015) Novel iron-based phosphate binders in patients with chronic kidney disease. Curr Opin Nephrol Hypertens 24:330–335PubMed

Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE, Wolf M, Chertow GM (2015) A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3-5. Am J Kidney Dis 65:728–736CrossRefPubMed

10.

Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, Chertow GM, Hirakata H (2014) Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis. J Ren Nutr 24:261–267CrossRefPubMed

11.

Lewis JB, Sika M, Koury MJ, Chuang P, Schulman G, Smith MT, Whittier FC, Linfert DR, Galphin CM, Athreya BP, Nossuli AK, Chang IJ, Blumenthal SS, Manley J, Zeig S, Kant KS, Olivero JJ, Greene T, Dwyer JP (2015) Ferric citrate controls phosphorus and delivers iron in patients on dialysis. J Am Soc Nephrol 26:493–503CrossRefPubMed

12.

Yokoyama K, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, Chertow GM, Hirakata H (2014) A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Nephrol Dial Transplant 29:1053–1060CrossRefPubMed

13.

Ardeshirpour L, Cole DE, Carpenter TO (2007) Evaluation of bone and mineral disorders. Pediatr Endocrinol Rev Suppl 1:584–598

14.

Chertow GM, Block GA, Neylan JF, Pergola PE, Uhlig K, Fishbane S (2017) Safety and efficacy of ferric citrate in patients with nondialysis-dependent chronic kidney disease. PLoS One 12:e0188712CrossRefPubMedPubMedCentral

15.

Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG (2005) Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 16:3070–3080CrossRefPubMed

16.

Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH (2006) The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol 1(Suppl 1):S9–S18CrossRefPubMed

17.

Girelli D, Trombini P, Busti F, Campostrini N, Sandri M, Pelucchi S, Westerman M, Ganz T, Nemeth E, Piperno A, Camaschella C (2011) A time course of hepcidin response to iron challenge in patients with HFE and TFR2 hemochromatosis. Haematologica 96:500–506CrossRefPubMed

18.

Saito H, Maeda A, Ohtomo S, Hirata M, Kusano K, Kato S, Ogata E, Segawa H, Miyamoto K, Fukushima N (2005) Circulating FGF-23 is regulated by 1alpha,25-dihydroxy vitamin D3 and phosphorus in vivo. J Biol Chem 280:2543–2549CrossRefPubMed

19.

Antoniucci DM, Yamashita T, Portale AA (2006) Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 91:3144–3149CrossRefPubMed

20.

Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16:2205–2215CrossRefPubMed

21.

Gupta A, Winer K, Econs MJ, Marx SJ, Collins MT (2004) FGF-23 is elevated by chronic hyperphosphatemia. The J Clin Endocrinol Metab 89:4489–4492CrossRefPubMed

22.

Farrow EG, Yu X, Summers LJ, Davis SI, Fleet JC, Allen MR, Robling AG, Stayrook KR, Jideonwo V, Magers MJ, Garringer HJ, Vidal R, Chan RJ, Goodwin CB, Hui SL, Peacock M, White KE (2011) Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A 108:E1146–E1155CrossRefPubMedPubMedCentral

23.

Clinkenbeard EL, Farrow EG, Summers LJ, Cass TA, Roberts JL, Bayt CA, Lahm T, Albrecht M, Allen MR, Peacock M, White KE (2014) Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice. J Bone Miner Res 29:361–369CrossRefPubMedPubMedCentral

24.

David V, Martin A, Isakova T, Spaulding C, Qi L, Ramirez V, Zumbrennen-Bullough KB, Sun CC, Lin HY, Babitt JL, Wolf M (2016) Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int 89:135–146CrossRefPubMedPubMedCentral

25.

Hanudel MR, Chua K, Rappaport M, Gabayan V, Valore E, Goltzman D, Ganz T, Nemeth E, Salusky IB (2016) Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice. Am J Physiol Renal Physiol 311:F1369–f1377CrossRefPubMedPubMedCentral

26.

Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB, Wolf M (2011) Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 79:1370–1378CrossRefPubMedPubMedCentral

27.

Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB (2003) Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64:2272–2279CrossRefPubMed

28.

Portale AA, Wolf M, Juppner H, Messinger S, Kumar J, Wesseling-Perry K, Schwartz GJ, Furth SL, Warady BA, Salusky IB (2014) Disordered FGF23 and mineral metabolism in children with CKD. Clin J Am Soc Nephrol 9:344–353CrossRefPubMed

29.

Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M (2011) Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 305:2432–2439CrossRefPubMedPubMedCentral

30.

Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P (2007) Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the mild to moderate kidney disease (M MKD) Study. J Am Soc Nephrol 18:2600–2608CrossRefPubMed

31.

Portale AA, Wolf MS, Messinger S, Perwad F, Juppner H, Warady BA, Furth SL, Salusky IB (2016) Fibroblast growth factor 23 and risk of CKD progression in children. Clin J Am Soc Nephrol 11:1989–1998CrossRefPubMedPubMedCentral

32.

Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro OM, Kusek JW, Keane MG, Wolf M (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121:4393–4408CrossRefPubMedPubMedCentral

33.

Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, de Filippi C, Wolf M (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119:2545–2552CrossRefPubMedPubMedCentral

34.

Mehta R, Cai X, Lee J, Scialla JJ, Bansal N, Sondheimer JH, Chen J, Hamm LL, Ricardo AC, Navaneethan SD, Deo R, Rahman M, Feldman HI, Go AS, Isakova T, Wolf M (2016) Association of fibroblast growth factor 23 with atrial fibrillation in chronic kidney disease, from the chronic renal insufficiency cohort study. JAMA Cardiol 1:548–556CrossRefPubMedPubMedCentral

35.

Mitsnefes MM, Betoko A, Schneider MF, Salusky IB, Wolf MS, Juppner H, Warady BA, Furth SL, Portale AA (2018) FGF23 and left ventricular hypertrophy in children with CKD. Clin J Am Soc Nephrol 13:45–52CrossRefPubMed

36.

Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584–592CrossRefPubMedPubMedCentral

37.

Souma N, Isakova T, Lipiszko D, Sacco RL, Elkind MS, DeRosa JT, Silverberg SJ, Mendez AJ, Dong C, Wright CB, Wolf M (2016) Fibroblast growth factor 23 and cause-specific mortality in the general population: the Northern Manhattan Study. J Clin Endocrinol Metab 101:3779–3786CrossRefPubMedPubMedCentral

38.

Yokoyama K, Hirakata H, Akiba T, Fukagawa M, Nakayama M, Sawada K, Kumagai Y, Block GA (2014) Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD. Clin J Am Soc Nephrol 9:543–552CrossRefPubMedPubMedCentral

39.

Iguchi A, Kazama JJ, Yamamoto S, Yoshita K, Watanabe Y, Iino N, Narita I (2015) Administration of ferric citrate hydrate decreases circulating FGF23 levels independently of serum phosphate levels in hemodialysis patients with iron deficiency. Nephron 131:161–166CrossRefPubMed

Title: Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients
Authors: Mark R. Hanudel
Marciana Laster
Georgina Ramos
Barbara Gales
Isidro B. Salusky
Publication date: 01-11-2018
Publisher: Springer Berlin Heidelberg
Published in: Pediatric Nephrology / Issue 11/2018
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-018-3999-y

ACC 2024 Congress

Springer Medicine

Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients

Abstract

Background

Methods

Results

Conclusions

ACC 2024 Congress

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2018

Nephrological and urological complications of homozygous c.974G>A (p.Arg325Gln) OSGEP mutations

Deriving and understanding the risk of post-transplant recurrence of nephrotic syndrome in the light of current molecular and genetic advances

Nephrotic syndrome associated with severe hypertriglyceridemia in a pediatric patient: Answers

Initial prednisolone dosing for the first relapse of steroid-sensitive nephrotic syndrome in Japanese children

Vitamin B6 blood concentrations in paediatric dialysis patients

Time-averaged hemoglobin values, not hemoglobin cycling, have an impact on outcomes in pediatric dialysis patients